PCI 3.06.26
Wallonia

Current Edition

Current Features

Biomanufacturing

Mastering ADC Bioconjugation: From DAR Control to Efficient Free Payload Removal

Continue reading

Upcoming Events

Elrig
Auto Draft
CPHI
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View
news

Adagio, after bold promises, says antibody drug won’t work well against omicron

The findings are a huge disappointment for Adagio, which billed ADG20 as a weapon that could neutralize a wide range of variants and help with future outbreaks. The c...
Continue Reading →
news

Roche cuts ties with Atea after COVID-19 pill’s trial failure

Roche's seeming lack of confidence in the future of AT-527 appears to be weighing on investors. Atea shares, which soared above $88 in February 2021, dropped 20% to b...
Continue Reading →
news

FDA approves Merck’s Keytruda as first immunotherapy for early kidney cancer

Approval of Keytruda in this setting comes about six months after Merck revealed early results from a study called Keynote-564, which showed the immunotherapy could h...
Continue Reading →
news

Biogen’s closely watched ALS drug comes up short in late-stage study

An experimental drug for amyotrophic lateral sclerosis missed the main goal of a late-stage clinical trial, marking another setback in attempts to treat the debilitat...
Continue Reading →
news

Merck advantage grows as FDA approves Keytruda for first-line cervical cancer

Merck's Keytruda is the dominant cancer immunotherapy and, of the seven of its type that are approved, the only that's cleared for use in cervical cancer, the fourth ...
Continue Reading →
news

Merck, Ridgeback seek US clearance of first oral COVID-19 drug

Merck’s filing comes less than two weeks after the drugmaker showed molnupiravir lowered the risk of hospitalization or death by roughly 50% in a Phase 3 trial, a res...
Continue Reading →
news

Hint of benefit in Alzheimer’s drug study fuel stock surge for Swiss biotech

A small clinical trial of a once-failed Alzheimer's drug offered tantalizing but inconclusive hints of benefit, propelling shares in its biotech maker higher by more ...
Continue Reading →

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience